Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
| ▸ | IKBKB | O14920 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15629835 | 0.87 | TERT (0.38) | TERTALDH1A1NOS2 | |
| SCHEMBL16091749 | 0.73 | TERT (0.40) | TERTALDH1A1 | |
| SCHEMBL16091777 | 0.70 | IKBKB (0.35) | KDM4EALDH1A1SMN1; SMN2NOS2IKBKB | |
| SCHEMBL25831616 | 0.68 | MAPT (0.35) | KDM4EALDH1A1 | |
| SCHEMBL16091762 | 0.68 | TLR8 (0.35) | KDM4EALDH1A1NOS2SKP2 | |
| SCHEMBL16091761 | 0.68 | CFB (0.38) | SMN1; SMN2NOS2 | |
| SCHEMBL3801326 | 0.67 | SKP2 (0.37) | KDM4EALDH1A1NOS2SKP2IKBKB | |
| SCHEMBL16091768 | 0.67 | KDM4E (0.35) | KDM4EALDH1A1NOS2IKBKB | |
| SCHEMBL3799895 | 0.66 | NOS2 (0.40) | KDM4EALDH1A1NOS2SKP2IKBKB | |
| SCHEMBL16091751 | 0.66 | MAOA (0.35) | KDM4EALDH1A1NOS2SKP2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340521-B2 | Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives | GREEN CROSS CORPORATION (KR) | 2016-05-17 | — | — | US | disclosed |
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | GREEN CROSS CORPORATION (KR) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274918-A1 | METHOD FOR DUAL INHIBITION OF SGLT1 AND SGLT2 USING DIPHENYLMETHANE DERIVATIVES | SLC5A2, SLC5A1, SLC10A2 | TERT 4595/4885KDM4E 767/4885ALDH1A1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.